Financial Toxicity as Drugs Move Earlier into Treatment Paradigm

Financial Toxicity as Drugs Move Earlier into Treatment Paradigm and How This Relates to Disparities in Treatment Patterns CME Available: https://auau.auanet.org/node/35729 Moderator: Jay D. Raman, MD, FACS Co-Hosts: Sarah Psutka, MD, MS LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Define the magnitude of financial toxicity/economic implications across GU malignancies currently. 2. Forecast the potential changes/increases in financial burden associated with moving systemic therapies earlier in treatment paradigms for patients with GU malignancies. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Astellas AstraZeneca Bayer Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc. Pfizer, Inc.

There are no comments yet.

Please log in to write the first comment.